4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $48.6 million.
- 4D Molecular Therapeutics' Cash & Equivalents fell 7410.94% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 7410.94%. This contributed to the annual value of $149.3 million for FY2024, which is 4005.17% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Cash & Equivalents stood at $48.6 million for Q3 2025, which was down 7410.94% from $77.2 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Cash & Equivalents ranged from a high of $275.7 million in Q3 2023 and a low of $48.6 million during Q3 2025
- For the 5-year period, 4D Molecular Therapeutics' Cash & Equivalents averaged around $157.8 million, with its median value being $149.3 million (2024).
- Per our database at Business Quant, 4D Molecular Therapeutics' Cash & Equivalents surged by 37584.19% in 2023 and then crashed by 7410.94% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Cash & Equivalents stood at $153.0 million in 2021, then plummeted by 65.78% to $52.4 million in 2022, then soared by 375.84% to $249.1 million in 2023, then plummeted by 40.05% to $149.3 million in 2024, then tumbled by 67.49% to $48.6 million in 2025.
- Its Cash & Equivalents was $48.6 million in Q3 2025, compared to $77.2 million in Q2 2025 and $133.5 million in Q1 2025.